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between rLR in 3TmMRI and the clinical variables, a logistic 
regression analysis was carried out. 
Results: In 14/57 patients (24.56%) a rLR through 3TmMRI 
was detected. Median pre-SRT PSA was 0.40 ng/ml 
(interquartile range, 0.30-2.05 ng/ml). The location of the 
recurrence was perianastomotic in 8/14 patients (57.14%) 
and retrovesical in 6/14 patients (42.86%). The median size 
of the local recurrence was 15.2 mm (range, 8.0-46.0 mm). 
The median apparent diffusion coefficient (ADC) value on 
DWI was 0.90 mm2/s (range, 0.35-1.58 mm2/s) and 6/14 
patients (42.85%) presented type 3 pathological captation 
curves and 3/14 patients (21.42%) presented type 2 
enhancement curves in the DCE images. Normal prostate 
tissue remains were identified in 9/57 patients (15.78%). 
Pelvic nodal recurrence was evidenced in 4/57 patients 
(7.01%) and pelvic bone metastasis were found in 4/57 
patients (7.01%). 12.90% (4/31) rLR was observed in patients 
with PSA ≤0.5 ng/ml, vs 38.46% (10/26) for PSA>0.5 ng/ml. 
The incidence of rLR according to PSA doubling time (PSADT) 
was 15.% (6/40) for PSADT≤14 months, vs 54.54% (6/11) for 
PSADT>14 months. The probability of rLR was significantly 
higher in patients with PSA levels >0.5 ng/ml (adjusted odds 
ratio (OR): 6.25; 95% confidence interval (CI): 1.27-
30.79;p=0.02), or PSA doubling time (PSADT)>14 months 
(adjusted OR: 7.12; 95% CI:1.40-36.25; p=0.01). 
Conclusions: This is the first study to find a significant 
relationship between the PSADT and the rLR through MRI. 
Patients that benefit most from conducting a 3TmMRI were 
those with PSADT>14 months or with pre-SRT PSA >0.5 ng/ml. 
Its routine use could have significant clinical implications in 
SRT.  
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Purpose/Objective: To eradicate all clonogenic cells within 
the gross tumor volume (GTV) and subclinical malignant 
disease area (CTV), for most cancers different radiation doses 
are prescribed to these volumes. This paradigm is however 
not routinely applied in prostate cancer. The entire gland is 
typically treated as GTV to a conventional dose of 78 Gy. 
Here, in higher risk patients, the treatment results are not 
sufficient, yet associated with mild to severe normal tissue 
toxicity. Derived from the histopathological properties, we 
propose to differentiate the dose between GTV and the CTV 
in the treatment of prostate cancer in order to increase the 
treatment results as well as reduce the risk of the treatment-
related toxicity.  
Materials and Methods: Twenty-five radical prostatectomy 
specimens were studied. The largest tumor focus was defined 
as index lesion. All index lesions and satellite tumor lesions 
≥0.5cm3 were set as GTV. The CTV was characterized as the 
whole gland excluding the GTV. Volume, cell density and 
Gleason score of index and satellite lesions were determined. 
This information was incorporated into radiobiological 
modeling of dose differentiation between GTV and CTV for 
these patients simulating the situation as if they were 
treated with radiotherapy. The tumor control probability 
(TCP) was modeled by assuming either a homogeneous or a 
heterogeneous α according to histopathological properties of 
tumor foci. For an α/β of 3, we chose the value for the 
homogeneous α (αhom) such that 80% TCP was reached in our 
population with a conventional dose of 78 Gy. The 
heterogeneous α varied with Gleason grade, keeping the 
weighted average over all tumors and Gleason grades equal 
to αhom. 
 
Results: 
 
 
Multifocal cancer was found in 76% (19/25) of the cases. The 
CTV of 12 cases of multifocal cancers (12/19) contained 
advanced pathology of GS 4+3 or 4+4. Compared to the GTV 
however, the pathology of CTV was on average more 
favorable. We found αhom=0.17 Gy-1 to reach 80% TCP with a 
conventional dose of 78 Gy. Here, a GTV dose of 81 Gy could 
be combined with a dose reduction to the CTV to 71 Gy 
without compromising the TCP in the population (Figure1a). 
Using a heterogeneous α however, α=0.212, 0.162 and 0.112 
Gy-1 for Gleason patterns 3, 4 and 5 respectively, a GTV dose 
of 89 Gy could be combined with a 70 Gy dose to the CTV 
while maintaining a TCP of 80% in the population (Figure1b). 
Conclusions: As subclinical prostate tumor foci may be 
clinically relevant, these need to be treated as CTV. If a 
homogeneous radiosensitivity for all tumor foci is considered, 
dose differentiation between GTV and CTV in the order of 10 
Gy may be feasible. Further dose differentiation can be 
achieved if Gleason grades are related to a heterogeneity in 
the radiosensitivity of the tumor foci. This may reduce the 
risk of the treatment-related toxicity without compromising 
local control. Further studies are needed to determine the 
effect of heterogeneous radiosensitivity on the response of 
individual patients to different regimes of radiotherapy.  
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